Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
SRA737 was said to be best in class and turned out to be right with two major companies discontinuing their CHK1’s!
It’s irrelevant as in SRA737 is only in class apart from a private company mentioned CHK1 by quote data, and SDC-1802 is the only Tyk2 biased/Selective TYK2/JAK1 inhibitor in Solid Tumors, not in B-Cell Lymphomas as Nimbus has a Tyk2, maybe best in class for SDC-1801 but will probably have to put in a full shift in with the BMS/Nimbus Very selective TYK2’s with all the good things being said by them!
Best in class means very little to the price its obviously commercially irrelevant at present
Hi RMM, we absolutely need some news if the improved comms around the AGM are not to be regarded as a sop to quieten the increasing frustrations expressed by the good folk on this board. The occasional re-tweet is better than nothing but we need a steady news flow to get the sp off the floor. The big concern has to be the likelihood of another raise and further dilution before the sp gets to a level anything like commensurate with the value of the ‘best in class’ assets. Whether next news is about SRI and lupus or confirmation of patent remains to be seen. It’s clear that people are starting to become ****ed off.... never mind the bang we don’t even get any fizz!!!
DNA damage ie SRA737 is a totally different mechanism to Immunotherapy, so immune checkpoint inhibitors has no relevance to a CHK1 Inhibitor, it’s totally different CHK1 is common too PARPS, ATM, ATR and Wee1 in that it stops Cancer repairing itself by breaking stopping stands on DNA!
Immune Checkpoint inhibitors use the body’s immune system to target cancer, PD-L1 and CTLA-4 are two kinds, TYK2/JAK1 is more closer to Immunotherapy as inhibits signals between Cancer and Immune System/Inflammation!
Celtic for all of he information posted on this board no one actually knows what’s going on that’s reality. The majority of positive people here predicted a license by February . I think there is zero probability but that’s ok
Hi Celtic. I think we were all quietly confident that 737 would be fast tracked until Sierra and NG started playing games. With Sierra looking for a non-dilutive partner the pause has been filled with competitive failures that make 737 look more of a risk than a guaranteed success. Some good news in Feb would allay fears. GLA
hi all. A bit confused here....I thought we were all quiet confident that our chk1 would be fast tracked for ano genetIail as initial data looked good?
Hi All
Here is another CHKpoint fail from a big player!
https://endpts.com/roches-tecentriq-stumbles-in-another-bladder-cancer-subset/
I tend to agree with RMM’s square wheel analogy however look at Merck’s Keytruda, which using a link to the same analogy “is rolling’!
Keytruda is performing very well in trials and has had some very positive read outs. It is now in blockbuster status. Therefore, the science is there and working but some ‘wheel makers’ just can’t ‘round the edges’ enough now. So has TM/JR found a way to make a ‘rounder wheel’ (best in class) - who knows for sure??????
GLA
I'm RMM and the square wheel thing. That is what I think. Just once i'd like to see positive data on CHK1 or TYK2 even if it is from a competitor. I also agree with Ahfam but with no deadline for the patent. IMO, the patent is the next news we are waiting for but I'm only guessing. Patents and the reporting of patents is a big bugbear of mine. Not just with SAR, I will add. They all do it. IMO, if we are investing our money into any company we should know the key dates for appeals etc.. We shouldn't be guessing when the appeal will be. I'm here for the end game but once I cash out. I'll only be using AIM to play.
Stoney - When I read through the patent extension I did think that they were going for so many cancer indications that it would take the reviewers/experts forever and a day to assess the application! However, I suspect that this is the norm. What Tim did say during the AGM was that we only need to be successful in 1 indication to get the ball rolling. If we're successful across multiple indications then its game on big time. I'm hoping that Ahfam is right and we can get patent approval in the next month but that's only wishful thinking. This is not an easy field when it comes to IP and patents. GLA
Nothing material- just my guess in terms of how long it should take the patent grant to happen and then the conclusion of negotiations which I believe are linked to the patent. I could be wrong it is Pharma after all.
Based on what ahfam , hope? We need to back over.045 p
We just need that patent grant and it's flood gates chaps. I'm still gunning for mid to late Feb for a deal.
Just reading through the US Patent extension/amendment for SDC-1802 from Nov 2019 and there are actually over 100+ cancer indications that can be treated (see section [0096]).
An extract reads as - "Examples of cancers (and their benign counterparts) that may be treated (or inhibited) include, but are not limited to tumours of epithelial origin (adenomas and carcinomas of various types including adenocarcinomas, squamous carcinomas, transitional cell carcinomas and other carcinomas) such as carcinomas of the.........." it then lists over 100 types.
All good stuff.........
Hi RMM - I agree, we need some news or at the minimum the data sets released to us that led to the selection of our SDC's. These data sets have been mentioned in numerous RNS's from Sareum and followed the collaboration with SRI and the 'optimisation' of our assets after multiple experiments in what would appear to be many indications both in auto-immune and cancer.
We know that the US Army data is subject to approval for release by them but as confirmed by SAR we are allowed to share with potential licencees/partners.
Also, I believe that these data sets were the basis of the amended/extended US patent applications which from memory covered 39 indications in autoimmune for SDC-1801 and over 50 types of cancer for SDC-1802.
Furthermore, TM stated on several occasions that the data sets were significant, striking, profound and compelling. IMHO the data sets are out with potential partners for due diligence and is one of the main reasons we are not seeing them - first refusal kind of scenario tied up in NDA's - I hope.......!!!!!! Why else would SAR be holding off issuing.....if they are so good!!!
GLA
Potnak/Stoney - We may be the 'only molecules left' but that doesn't necessarily mean we become the most valuable. If all around us are failing then the pharmas and markets may start to look at the sector as very high risk and actually price down. The best option for us is to get into a rising market where our product is one of a limited number of 'successes' available which then catalyses an auction. Eli Lilly having spent $1.6bn on a failed product creates fear rather than confidence. As a crude analogy, if a number of people invented the square wheel and the concept fails (for obvious reasons) then the last person with a square wheel does not have the most valuable option! My point is that we either need convincing data that our product works where others fail or we are a valuable alternative to a small number of products that are already succeeding. As you say Stoney the products have got to speak for themselves! We need some news!!! GLA
Hi Potnak - I believe the due diligence by potential licensees will allay any caution - as TM always states 'best in class' !
The science should speak for itself.........and is why we all remain invested.
GLA
Hi Ajithoth - I'm more interested in the licenses or T/O of our TYK2's SDC-1801 and SDC-1802 than the Chk1 SRA737.
We only have 27% stake in SRA737 but 100% in our SDC's.
IMHO - Our 'real' value is in the SDC's
The question is. Do all these failures increase the value of SAR's compounds or will big pharma be more cautious?
I'm half wondering if srra are just watching and waiting for other pharmas failure to strengthen their poker game......
Hi All - news from Endpoints - $1.6Bn fail
https://endpts.com/eli-lillys-1-6b-cancer-drug-failed-to-spark-even-the-slightest-positive-gain-for-patients-in-its-1st-phiii/
Details of the deal from 2018
https://www.biospace.com/article/eli-lilly-drops-1-6-billion-for-armo-biosciences-and-its-phase-iii-immuno-oncology-drug/
At this months Biospace in San Francisco - Eli Lilly CEO/CFO confirmed they are now re-targeting its pipeline under the guidance of the Loxo Oncology R&D team with the desire to acquire 'early stage' assets to boost its I/O pipeline and not get left behind - they talked about committing up to $ 20 Bn on bolstering the pipeline with deals to be announced each operating quarter.......